Pelagospharma
8 employees on LinkedIn · 1 known investors
Pelagos Pharma develops drugs targeting hard-to-treat receptors for age-related diseases, with a focus on extending healthspan and longevity.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $540.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Pelagospharma do?
- Pelagos Pharma develops drugs targeting hard-to-treat receptors for age-related diseases, with a focus on extending healthspan and longevity.
- Who are Pelagospharma's investors?
- Pelagospharma's investors include Portal Innovations.